AGP Executive Report
Last update: 12 hours agoCBD Clinical Update: Avecho is set to release interim phase III insomnia results for its synthetic CBD therapy, a study of about 520 patients using 75mg or 150mg nightly doses for eight weeks, with the company calling it the world’s biggest phase III CBD-and-sleep trial. Oncology Care: A symposium report highlights medical cannabis as a “multimodal” option for oncology nurses, aiming to reduce polypharmacy by targeting pain, nausea, appetite loss, anxiety, and sleep issues. Policy & Access: In the US, Ohio lawmakers are “pushing pause” on marijuana law changes for now, while Wisconsin remains a no-marijuana state even if products are bought legally elsewhere (CBD is legal). Regulation Pushback: Ghana’s cannabis industry chamber is defending the sector after NACOC arrested Central University students over cannabis-infused sweets, warning that unfinished licensing rules and repeated arrests could chill investment. Enforcement Spotlight: Nigeria’s NDLEA reports arrests of two elderly men accused of supplying illicit drugs to secondary school students in Abia, plus other drug seizures including synthetic cannabinoids and cannabis. Travel/Use Reality Check: Fiji’s cannabis ban reportedly blocked a medical marijuana patient from bringing his prescription during “Winners at War.”
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
